Search | Clinical Trials Finder

Conditions: Hemophilia B
Interventions: rFIXFc; Biological
Lead sponsor: Bioverativ, a Sanofi company; Industry
Eligibility: Up to 17 Years · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 11
States / cities: Sacramento, California • Washington D.C., District of Columbia • Atlanta, Georgia + 8 more

Conditions: Factor IX Deficiency
Interventions: Standard care with blood and urine sample collection; Other
Lead sponsor: Skane University Hospital; Other
Eligibility: Not listed
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hemophilia B
Interventions: rIX-FP; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: Up to 70 Years · Male only
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 4
States / cities: Aurora, Colorado • Indianapolis, Indiana • Philadelphia, Pennsylvania + 1 more

Conditions: Hemophilia B
Interventions: AAV8-hFIX19; Biological
Lead sponsor: Spark Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Hemophilia B
Interventions: PF-06838435/ fidanacogene elaparvovec; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2031
U.S. locations: 17
States / cities: San Francisco, California • Aurora, Colorado • Indianapolis, Indiana + 3 more

Conditions: Traumatic Injury
Interventions: BE1116, Placebo; Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 15 Years and older
Enrollment: 1,366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 90
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 79 more

Conditions: Hemophilia B
Interventions: rFIXFc; Drug
Lead sponsor: Bioverativ Therapeutics Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 6
States / cities: Chicago, Illinois • Indianapolis, Indiana • Boston, Massachusetts + 3 more

Conditions: Blood Coagulation Disorders, Acute Major Bleeding
Interventions: Beriplex® P/N (Kcentra), Fresh frozen plasma; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 41
States / cities: Birmingham, Alabama • Los Angeles, California • San Franciso, California + 33 more

Conditions: Hemophilia B
Interventions: Not listed
Lead sponsor: Bloodworks; Other
Eligibility: 16 Years and older · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: Los Angeles, California • San Diego, California • New Orleans, Louisiana + 2 more

Conditions: Hemophilia B
Interventions: SPK-9001; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 9
States / cities: Sacramento, California • Jackson, Mississippi • Madison, Mississippi + 2 more

Conditions: Hemophilia B
Interventions: AAV5-hFIXco-Padua, Factor IX (FIX); Genetic · Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 19
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 14 more

Conditions: Hemophilia A, Hemophilia B
Interventions: Recombinant Factor VIIa BI (rFVIIa BI); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Hemophilia B
Interventions: Non-Interventional; Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 16 Years and older · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 9
States / cities: Aurora, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 6 more

Conditions: Hemophilia B
Interventions: Adeno-Associated Viral with Human Factor IX; Genetic
Lead sponsor: Avigen; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 3
States / cities: Palo Alto, California • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Hemorrhage
Interventions: Kcentra®, Plasma; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 2,238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Oakland, California

Conditions: Severe Hemophilia B
Interventions: Factor IX (rFIXFc), rFIX; Drug
Lead sponsor: Bioverativ Therapeutics Inc.; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 9
States / cities: Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 6 more

Conditions: Hemophilia, Menstrual Flow Excessive
Interventions: Recombinant FVIII Fc fusion product Eloctate, Recombinant FIX Fc fusion product Alprolix, Patient-operated diagnostic device for anemia AnemoCheck.; Drug · Device
Lead sponsor: Emory University; Other
Eligibility: 14 Years to 55 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hemophilia
Interventions: Fitusiran, BPA prophylaxis, Factor (FVIII or FIX) prophylaxis; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Haemophilic Pseudotumour
Interventions: Emicizumab; Drug
Lead sponsor: Indiana Hemophilia &Thrombosis Center, Inc.; Other
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hemophilia
Interventions: Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013, Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013; Biological
Lead sponsor: American Thrombosis and Hemostasis Network; Network
Eligibility: Not listed
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 27
States / cities: San Diego, California • Aurora, Colorado • New Haven, Connecticut + 23 more

Conditions: Hemophilia A
Interventions: Nuwiq, Octanate, Wilate, Emicizumab, Recombinant factor VIIa (rFVIIa), Activated prothrombin complex concentrate (aPCC); Biological
Lead sponsor: Emory University; Other
Eligibility: Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Heart Disease End Stage, Heart Failure，Congestive
Interventions: Kcentra, Frozen Plasma Product, Human; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 3
States / cities: Baltimore, Maryland • Pittsburgh, Pennsylvania

Conditions: Hemophilia A With Inhibitors, Hemophilia B With Inhibitors
Interventions: Coagulation FVIIa (Recombinant); Biological
Lead sponsor: Laboratoire français de Fractionnement et de Biotechnologies; Industry
Eligibility: Up to 11 Years · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 3
States / cities: Aurora, Colorado • Oklahoma City, Oklahoma • Dallas, Texas

Conditions: Significant Bleeding Risk
Interventions: Octaplex, Beriplex P/N (Kcentra); Drug
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 22
States / cities: Aurora, Colorado • New Haven, Connecticut • Miami, Florida + 14 more

Search by objective public record fields.

Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B

Natural History Study of Factor IX Treatment and Complications

A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

Hemophilia B Gene Therapy With AAV8 Vector

A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B

Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )

Phase I/IIa Study of FIXFc in Hemophilia B Patients

Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy

Joint Health Study

A Gene Therapy Study for Hemophilia B

HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients

Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen

A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy

Safety of a New Type of Treatment Called Gene Transfer for the Treatment of Severe Hemophilia B

An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding

Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B

Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers

A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis

HemLibra Prophylaxis in Patients With Hemophilic Pseudotumor

ATHN 2: Factor Switching Study

Treatment of Hemophilia A Patients With FVIII Inhibitors

Administration of Prothrombin Complex Concentrate vs. Standard Transfusion During/After Heart Transplantation

A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa

Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.